High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS)

Blood

Volumn 112, Issue 7, 2008, Pages 2703-2708

  Ay, Cihan ^a   Simanek, Ralph ^a   Vormittag, Rainer ^a   Dunkler, Daniela ^b   Alguel, Guelay ^a   Koder, Silvia ^a   Kornek, Gabriela ^c   Marosi, Christine ^c   Wagner, Oswald ^d   Zielinski, Christoph ^c   Pabinger, Ingrid ^a,d  

^a Clinical Division of Haematology and Haemostaseology   (Austria)

^b Section of Clinical Biometrics   (Austria)

^c Department of Medicine I

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CLOPIDOGREL; LOW MOLECULAR WEIGHT HEPARIN; PADGEM PROTEIN; TICLOPIDINE;

ADULT; AGED; ARTICLE; BRAIN TUMOR; BREAST TUMOR; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TUMOR; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; KIDNEY TUMOR; MAJOR CLINICAL STUDY; MALE; PANCREAS TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE TUMOR; PROTEIN BLOOD LEVEL; RISK FACTOR; VENOUS THROMBOEMBOLISM; ANTIBODY SPECIFICITY; AUSTRIA; BLOOD; KAPLAN MEIER METHOD; MIDDLE AGED; NEOPLASM; PROPORTIONAL HAZARDS MODEL; SOLUBILITY;

AGED; AUSTRIA; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; ORGAN SPECIFICITY; P-SELECTIN; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SOLUBILITY; VENOUS THROMBOEMBOLISM;

EID: 53449093751     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-142422     Document Type: Article

References (50)

1. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6: 401-410.
2. Lee AY. Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res. 2003;110:167-172.
3. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585-593.
4. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343: 1846-1850.
5. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrentthromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78:285-291.
6. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006;118:555-568.
7. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost. 2007;5(Suppl 1):246-254.
8. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost. 2005;31:104-110.
9. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002;4:465-473.
10. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood. 1983;62:14-31.
11. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest. 2003: 124(suppl):58-68.
12. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96:3302-3309.
13. Falanga A, Marchetti M, Vignoli A, Balducci D. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol. 2003;1:673-678.
14. Wahrenbrock M, Borsig L, Le D, Varki N, Varki A. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest. 2003;112:853-862.
15. Chen M, Geng JG. P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp (Warsz). 2006;54:75-84.
16. Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A. 2000;97:13835-13840.
17. Polgar J, Matuskova J, Wagner DD. The P-selectin, tissuefactor, coagulation triad. J Thromb Haemost. 2005;3:1590-1596.
18. Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost. 2004;92:459-466.
19. Celi A, Pellegrini G, Lorenzet R, et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A. 1994;91:8767-8771.
20. del Conde I, Nabi F, Tonda R, Thiagarajan P, Lopez JA, Kleiman NS. Effect of P-selectin on phosphatidylserine exposure and surfacedependent thrombin generation on monocytes. Arterioscler Thromb Vase Biol. 2005;25:1065-1070.
21. Gupta GP, Massague J. Platelets and metastasis revisited: a novel fatty link. J Clin Invest. 2004; 114:1691-1693.
22. Aigner S, SthoegerZM, Fogel M, et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood. 1997;89:3385-3395.
23. Aigner S, Ramos CL, Hafezi-Moghadam A, et al. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEBJ. 1998;12:1241-1251.
24. Friederichs J, Zeller Y, Hafezi-Moghadam A, Grone HJ, Ley K, Altevogt P. The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res. 2000;60:6714-6722.
25. Reyes-Reyes ME, George MD, Roberts JD, Akiyama SK. P-selectin activates integrinmediated colon carcinoma cell adhesion to fibronectin. Exp Cell Res. 2006;312:4056-4069.
26. Ay C, Jungbauer LV, Sailer T, et al. High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem. 2007;53: 1235-1243.
27. Blann AD, Noteboom WM, Rosendaal FR. Increased soluble P-selectin levels following deep venous thrombosis: cause or effect? Br J Haematol. 2000;108:191-193.
28. Rectenwald JE, Myers DD Jr, HawleyAE, et al. D-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study. Thromb Haemost. 2005;94:1312-1317.
29. Kyrle PA, Hron G, Eichinger S, Wagner O. Circulating P-selectin and the risk of recurrent venous thromboembolism. Thromb Haemost. 2007;97: 880-883.
30. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-3488.
31. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18:3078-3083.
32. Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer. 2007;110:1149-1161.
33. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343-346.
34. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-815.
35. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715-722.
36. Ambrus JL. Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med. 1975; 6:61-64.
37. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(suppl):338-400.
38. Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 2002;87:1076-1077.
39. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4:529-535.
40. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005; 104:2822-2829.
41. Myers DD Jr, Rectenwald JE, Bedard PW, et al. Decreased venous thrombosis with an oral inhibitor of P selectin. J Vasc Surg. 2005;42:329-336.
42. Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res. 2005;11: 7003-7011.
43. Myers DD Jr, Wrobleski SK, Longo C, et al. Resolution of venous thrombosis using a novel oral small-molecule inhibitor of P-selectin (PSI-697) without anticoagulation. Thromb Haemost. 2007; 97:400-407.
44. Ludwig RJ, Alban S, Bistrian R, et al. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost. 2006;95:535-540.
45. Ludwig RJ, Boehme B, Podda M, et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. 2004;64:2743-2750.
46. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins: implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest. 1998;101:877-889.
47. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23:2123-2129.
48. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22:1944-1948.
49. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23:2130-2135.
50. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004; 2:1266-1271.